Find a consultant

Our consultant directory offers information on who our consultants are, their specialities and where they are based.

If you have an enquiry relating to your appointment or your treatment, you should contact the relevant department instead of your individual consultant to ensure that our clinical support team can provide you with the right support to your enquiry in a timely manner.

Dr John Riches

Consultant at St Bartholomew's Hospital

Dr John Riches is a consultant haematologist at Barts Health NHS Trust specialising in the management of lymphoid malignancies. He trained at Oxford and Cambridge Universities qualifying in 2003. He undertook Haematology training based at Hammersmith Hospital, Imperial College NHS Trust being awarded membership of the Royal College of Physicians in 2006 and Fellowship of the Royal College of Pathologists in 2015. He has completed an PhD in the immunobiology of chronic lymphocytic leukaemia in 2013, being awarded the Hamblin prize by the UK CLL Forum for his research in 2014. He has published over 30 peer-reviewed articles on areas of lymphoma and CLL including several articles in Blood, Science Immunology and the Journal of Clinical Investigation, and is a regular presenter at national and international conferences.

Dr Riches is an investigator on a number of national UK lymphoma and chronic lymphocytic leukaemia trials, is a core member of UK CLL Forum and  NCRI lymphoma subgroup, and is a member of the BSCH guideline writing groups for various lymphoid cancers. In addition to his clinical activities he leads a research group at Barts Cancer Institute. 

Treatments and procedures

Management of lymphoid malignancies including all types of Hodgkin and non-Hodgkin lymphoma and lymphoid leukaemias including CLL. Expertise in standard chemotherapy, targeted therapies, immunotherapy and bone marrow transplantation

Research interests

Dr Riches’ major research interest is investigating the alterations in metabolism that accompany B-cell activation and how this is reflected in the metabolism of low- and high grade lymphomas including chronic lymphocytic leukaemia/small lymphocytic lymphoma, follicular lymphoma, diffuse large B cell lymphoma and Burkitt lymphoma. His team uses a variety of proteomic and metabolomic techniques to study these questions in primary patient samples, B-cell lines and murine conditional knockout and transgenic lymphoma models.  They are particularly interested in the impact of genetic aberrations of MYC and p53 on the metabolism of lymphoma cells and how this relates to high grade transformation of CLL (Richter syndrome). Their overall aim is that an enhanced understanding of the metabolism of normal and malignant B cells will underpin the development of the next generation of anti-metabolic drugs for these cancers and may also be of benefit in the treatment of non-malignant autoimmune conditions. 

Leadership roles

Dr Riches is involved in teaching undergraduate and MSc students and is the course director for the MSc Cancer & Clinical Oncology Programme.
Speciality
Consultant services Cancer
Languages Spoken English
GMC number 6075461
Record last modified